

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|----|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|----|--|

No equality issues identified during the scoping process.

- | | |
|----|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|----|---|

No other equality issues raised.

- | | |
|----|---|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----|---|

Not applicable.

- | | |
|----|---|
| 4. | Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|----|---|

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, section 3.17 of draft guidance.

Approved by Associate Director (name): Christian Griffiths [Principal Technical Adviser]

Date: 29 April 2025